News

Stock of Uniqlo’s Parent Down Most in 9 Weeks After Xinjiang Remarks

(Bloomberg) -- Shares of Fast Retailing declined as much as 4.5%, the most since Sept. 30, after a spokesperson said the company is concerned about Chinese demand following comments from its chairman that the retailer is not using cotton from Xinjiang. Most Read from BloombergRiyadh Metro Partially Opens in Bid to Ease City’s Traffic JamsIn Traffic-Weary Toronto, a Battle Breaks Out Over Bike LanesTadashi Yanai said Fast Retailing’s flagship clothing chain Uniqlo does not source cotton from Chin

Stocks Versus Bonds Dilemma Hits EM Traders as Trump Returns

(Bloomberg) -- Investors are scrambling to decide if Donald Trump’s impending return to the White House will sustain or derail the rally in emerging-market bonds witnessed under Joe Biden.Most Read from BloombergRiyadh Metro Partially Opens in Bid to Ease City’s Traffic JamsAs Wars Rage, Cities Face a Dark New Era of Urban DestructionAccording to Jeff Grills, head of US cross-asset and emerging-markets debt at Aegon Asset Management, whether equities or bonds benefit most from Trump’s second pre

Advent Eyes New Mid-Market Strategy for Smaller Deals

(Bloomberg) -- Buyout firm Advent is contemplating setting up an investment vehicle targeting mid-sized transactions as it looks to bolster its core private equity business.Most Read from BloombergRiyadh Metro Partially Opens in Bid to Ease City’s Traffic JamsAs Wars Rage, Cities Face a Dark New Era of Urban DestructionAdvent, which is focused on buying controlling stakes in businesses, raised $25 billion for its flagship buyout fund in 2022 — its largest fundraising to date. The firm sees a “fi

Why Is Purple Biotech Stock Trading Higher On Monday?

On Monday, Purple Biotech Ltd (NASDAQ:PPBT) reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic ductal adenocarcinoma (PDAC). Purple Biotech stock is trading higher with a strong session volume of 9.7 million, compared to an average volume of 48.73K as per data from Benzinga Pro. The Phase 2 study evaluated CM24 in combination with Bristol Myers Squibb & Co’s (NYSE:BMY) immu